Sutimlimab vs placebo in cold agglutinin disease, the impact of etoposide versus auto-transplant in PTCL, and the role of pulmonary NETs in sickle cell disease

episode

Blood Podcast not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

Related

recent transcribed audio

Board of County Supervisors - Joint Meeting with the School Board - Sep 23, 2026 2h 59m · 25 Sep 2026 · Prince William County Board of Supervisors

The Ezra Klein Show: Jensen Huang Thinks A.I. Alarmism Has Gone Too Far 1h 50m · 25 Sep 2026 · Hard Fork

Costco checks out strong 4 min · 25 Sep 2026 · Wall Street Breakfast

SCOTUS voter ID ruling, Xi wraps DC visit, New Zealand's farmers (Update) 10 min · 25 Sep 2026 · Reuters World News

New York Knicks Season Preview 33 min · 25 Sep 2026 · The Athletic NBA Daily

How Preparation Creates Confidence Before the Money Comes 3 min · 25 Sep 2026 · The Level Up Podcast w/ Paul Alex

Report any issue

Source

Recorded01 Sep 2022

Publisherfeeds.transistor.fm ↗

Handlerec:11742071

Show notes

In this week’s episode, we review results of a randomized, placebo-controlled phase 3 trial demonstrating that targeted inhibition of C1s with the monoclonal antibody sutimlimab is effective and well tolerated in non-transfusion-dependent patients with cold agglutinin disease. We’ll also review a population-based study evaluating the impact of adding either etoposide or autologous stem cell transplantation to CHOP in young and fit patients with peripheral T cell lymphomas. Finally, we’ll review a paper that elucidates a mechanism of lung injury in sickle cell disease. It involves gasdermin-D-dependent production of neutrophil extracellular traps in the liver, which travel intravascularly to the lung, where they promote occlusion of the pulmonary microcirculation.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in